- Home
- CRDL vs GEVO Comparison
CRDL vs GEVO Comparison
Compare CRDL & GEVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRDL
- GEVO
- Stock Information
- Founded
- CRDL 2017
- GEVO 2005
- Country
- CRDL Canada
- GEVO United States
- Employees
- CRDL N/A
- GEVO N/A
- Industry
- CRDL Biotechnology: Biological Products (No Diagnostic Substances)
- GEVO Major Chemicals
- Sector
- CRDL Health Care
- GEVO Industrials
- Exchange
- CRDL Nasdaq
- GEVO Nasdaq
- Market Cap
- CRDL 105.8M
- GEVO 246.8M
- IPO Year
- CRDL N/A
- GEVO 2011
- Fundamental
- Price
- CRDL $1.39
- GEVO $1.41
- Analyst Decision
- CRDL Strong Buy
- GEVO Buy
- Analyst Count
- CRDL 2
- GEVO 2
- Target Price
- CRDL $9.00
- GEVO $7.58
- AVG Volume (30 Days)
- CRDL 226.6K
- GEVO 5.2M
- Earning Date
- CRDL 08-11-2025
- GEVO 08-07-2025
- Dividend Yield
- CRDL N/A
- GEVO N/A
- EPS Growth
- CRDL N/A
- GEVO N/A
- EPS
- CRDL N/A
- GEVO N/A
- Revenue
- CRDL N/A
- GEVO $42,034,000.00
- Revenue This Year
- CRDL N/A
- GEVO $1,022.79
- Revenue Next Year
- CRDL N/A
- GEVO $12.26
- P/E Ratio
- CRDL N/A
- GEVO N/A
- Revenue Growth
- CRDL N/A
- GEVO 145.38
- 52 Week Low
- CRDL $0.77
- GEVO $0.48
- 52 Week High
- CRDL $2.63
- GEVO $3.39
- Technical
- Relative Strength Index (RSI)
- CRDL 54.70
- GEVO 60.92
- Support Level
- CRDL $1.22
- GEVO $1.17
- Resistance Level
- CRDL $1.50
- GEVO $1.39
- Average True Range (ATR)
- CRDL 0.10
- GEVO 0.10
- MACD
- CRDL -0.01
- GEVO 0.01
- Stochastic Oscillator
- CRDL 60.71
- GEVO 85.71
About CRDL Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.
About GEVO Gevo Inc.
Gevo Inc is a renewable chemicals and biofuels company engaged in the development and commercialization of alternatives to petroleum-based products based on isobutanol produced from renewable feedstocks. The operating segments are the Gevo segment, GevoFuels segment, and the GevoRNG segment. By its segments, it is involved in research and development activities related to the future production of SAF, commercial opportunities for other renewable hydrocarbon products and isobutanol, including the development of its biocatalysts, and the produces-pipeline quality methane gas captured from dairy cow manure. The company derives maximum revenue from the GevoRNG segment.